The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1026-1035

  Meers, Stef ^a,b   Vandenberghe, Peter ^a   Boogaerts, Marc ^a   Verhoef, Gregor ^a   Delforge, Michel ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Flow cytometry; HUMARA; Lymphocytes; Myelodysplastic syndromes; T cell activation

Indexed keywords

C REACTIVE PROTEIN; CD28 ANTIGEN; CD57 ANTIGEN; HLA DR3 ANTIGEN; L SELECTIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IRON CHELATION; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; X CHROMOSOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION;

EID: 41949110665     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.004     Document Type: Article

References (48)

1. Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J 4 (2003) 303-309
2. Hamblin T.J. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33 (1996) 150-162
3. Selleri C., Maciejewski J.P., Catalano L., Ricci P., Andretta C., Luciano L., et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia. Cancer 95 (2002) 1911-1922
4. Saunthararajah Y., Molldrem J.J., Rivera M., Williams A., Stetler-Stevenson M., Sorbara L., et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 112 (2001) 195-200
5. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 1314-1322
6. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J.J., and Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25 (2001) 1075-1083
7. Melenhorst J.J., Eniafe R., Follmann D., Nakamura R., Kirby M., and Barrett A.J. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndromes. Br J Haematol 119 (2002) 97-105
8. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106 (2005) 841-851
9. Wlodarski M.W., Gondek L.P., Nearman Z.P., Plasilova M., Kalaycio M., Hsi E.D., et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 108 (2006) 2632-2641
10. Epling-Burnette P.K., Painter J.S., Rollison D.E., Ku E., Vendron D., Widen R., et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 21 (2007) 659-667
11. Kook H., Zeng W., Guibin C., Kirby M., Young N.S., and Maciejewski J.P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 29 (2001) 1270-1277
12. Aivado M., Rong A., Stadler M., Germing U., Giagounidis A., Strupp C., et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68 (2002) 210-216
13. Molldrem J., Caples M., Mavroudis D., Plante M., Young N.S., and Barrett A.J. Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndrome. Br J Haematol 99 (1997) 699-705
14. Tichelli A., Gratwohl A., Wuersch A., Nissen C., and Speck B. Antilymphocyte globulin formyelodysplastic syndrome?. Br J Haematol 68 (1988) 139-140
15. Broliden P.A., Dahl I.M., Hast R., Johansson B., Juvonen E., Kjeldsen L., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 (2006) 667-670
16. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102 (2003) 3025-3027
17. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100 (2002) 1570-1574
18. Delforge M., Demuynck H., Vandenberghe P., Verhoef G., Zachee P., van Duppen V., et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86 (1995) 3660-3667
19. Lyon M.F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190 (1961) 372-373
20. Van den Hove L.E., Symons F., Vandenberghe P., Verhoef G.E., Demuynck H., Van Gool S.W., et al. Multivariate reconstruction of lymphocyte profiles in a two-dimensional graphical model as a tool for the investigation of lymphocyte subset distribution in health and disease. Cytometry 28 (1997) 220-227
21. Bynoe A.G., Scott C.S., Ford P., and Roberts B.E. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol 54 (1983) 97-102
22. Colombat P.H., Renoux M., Lamagnere J.-P., and Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer 61 (1988) 1075-1081
23. Symeonidis A., Kourakli A., Katevas P., Perraki M., Tiniakou M., Matsouka P., et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 47 (1991) 277-281
24. Baumann I., Scheid C., Koref M.S., Swindell R., Stern P., and Testa N.G. Autologous lymphocytes inhibit hemopoiesis in long-term cultures in patients with myelodysplastic syndromes. Exp Hematol 30 (2002) 1405-1411
25. Molldrem J., Rivera M., and Bahceci E. Treatment of bone marrow failure of myelodysplastic syndrome with antithymocyte globulin. Ann Intern Med 137 (2002) 156-163
26. Shimamoto T., Tohyama K., and Okamoto T. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 27 (2003) 783-788
27. Barrett J., Sloand E., and Young N. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment. Haematologica 91 (2006) 583-584
28. Amin H.M., Jilani I., Estey E.H., Keating M.J., Dey A.L., Manshouri T., et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 102 (2003) 1866-1868
29. Champion K.M., Gilbert J.G., Asimakopoulos F.A., Hinshelwood S., and Green A.R. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol 97 (1997) 920-926
30. Prchal J.T., Throckmorton D.W., Carroll III A.J., Fuson E.W., Gams R.A., and Prchal J.F. A common progenitor for human myeloid and lymphoid cells. Nature 274 (1978) 590-591
31. Tefferi A., Thibodeau S.N., and Solberg Jr. L.A. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 75 (1990) 1770-1773
32. Culligan D.J., Cachia P., Whittaker J., Jacobs A., and Padua R.A. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81 (1992) 346-352
33. Okada M., Okamoto T., Takemoto Y., Kanamaru A., and Kakishita E. Function and X chromosome inactivation analysis of B lymphocytes in myelodysplastic syndromes with immunological abnormalities. Acta Haematol 102 (1999) 124-130
34. Tsukamoto N., Morita K., Maehara T., Okamoto K., Karasawa M., Omine M., and Naruse T. Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83 (1993) 589-594
35. Abrahamson G., Boultwood J., Madden J., Kelly S., Oscier D.G., Rack K., et al. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses. Br J Haematol 79 (1991) 550-555
36. Anan K., Ito M., Misawa M., Ohe Y., Kai S., Kohsaki M., et al. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene. Br J Haematol 89 (1995) 838-844
37. Van Kamp H., Fibbe W., Jansen R., Vander Keur M., De Graaff E., Willemze R., et al. Clonal involvement of granulocytes and monocytees, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis of X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phophoglycerate kinase gene. Blood 80 (1992) 1774-1780
38. Delforge M., Demuynck H., Verhoef G., Vandenberghe P., Zachee P., Maertens J., et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 102 (1998) 486-494
39. Boultwood J., and Wainscoat J. Clonality in the myelodysplastic syndromes. Int J Hematol 73 (2001) 411-415
40. Lazuardi L., Jenewein B., Wolf A.M., Pfister G., Tzankov A., and Grubeck-Loebenstein B. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 114 (2005) 37-43
41. Sternberg A., Killick S., Littlewood T., Hatton C., Peniket A., Seidl T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106 (2005) 2982-2991
42. Tajima F., Kawatani T., Endo A., and Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 10 (1996) 478-482
43. Aw D., Silva A.B., and Palmer D.B. Immunosenescence: emerging challenges for an ageing population. Immunology 120 (2007) 435-446
44. Fujii S., Shimizu K., Klimek V., Geller M.D., Nimer S.D., and Dhodapkar M.V. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 122 (2003) 617-622
45. Ogata K., Fujii H., Yokose N., An E., Tamura H., Kamikubo K., et al. Defective natural killer (NK) cell-mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes. Br J Haematol 87 (1994) 396-398
46. Kiladjian J.J., Bourgeois E., Lobe I., Braun T., Visentin G., Bourhis J.H., et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20 (2006) 463-470
47. Ling M., Delforge M., van Duppen V., Verhoef G., Emanuel B., Boogaerts M., et al. Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 18 (2004) 1451-1456
48. Miura I., Kobayashi Y., Takahashi N., Saitoh K., and Miura A. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol 110 (2000) 876-879